uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Friday. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.25, Zacks reports. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

uniQure Stock Up 4.3 %

Shares of QURE opened at $12.78 on Friday. The firm’s 50-day simple moving average is $12.22 and its 200 day simple moving average is $12.09. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market cap of $700.04 million, a P/E ratio of -2.58 and a beta of 0.10. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. Wells Fargo & Company cut their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a report on Monday, April 21st. StockNews.com upgraded uniQure to a “sell” rating in a research note on Tuesday, March 11th. Finally, Chardan Capital reissued a “buy” rating and issued a $38.00 price objective on shares of uniQure in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This represents a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 over the last quarter. Company insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.